RxDoctor Payments Data

Edward Engle, DO

Otolaryngology · Manahawkin, NJNPI 1417021627

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by GSK at 34.0% of the total. 2025 is the largest year on record at $221, 3.8 times the $57 reported in 2019. That places this record below the midpoint for otolaryngology clinicians in NJ, where the typical reported total is $1,314.

$777in general payments, 2019–2025

Across 44 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$264
  • Regeneron Healthcare Solutions, Inc.$204
  • Optinose US, Inc.$160
  • Sanofi$75
  • Integra Lifesciences Corporation$36
  • Paratek Pharmaceuticals, Inc.$19
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$777100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$777 in reported general payments places this provider in the 35th percentile of 232 otolaryngology providers in New Jersey.

See all otolaryngology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$424,063
Medicare patients
946
Services billed
10,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Olopatadine Hcl86$7,722
Ipratropium Bromide160$6,533
Montelukast Sodium225$4,320
Azelastine-FluticasoneAzelastine/Fluticasone17$4,268
Fluticasone Propionate218$4,196
Azelastine Hcl127$3,759
SingulairMontelukast Sodium12$3,175
Mometasone Furoate18$2,850
Fluocinolone Acetonide Oil43$2,111
Epinephrine12$1,870
Desloratadine42$1,716
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth15$1,575
Famotidine113$1,273
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc46$944
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort16$770

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Manahawkin

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →